Michael David Schuster

This inventor holds 5 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignee: Mesoblast, Inc. Active years: 2014-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael David Schuster. Retrieved from https://idiyas.com/inventor/michael-david-schuster

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 11(Granted Patents)

Company Filing History:

5 out of 31

Mesoblast, Inc

patents

Years Active: 2014-2020

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10849932 - Method of treating graft versus host disease (2020-12-01),

2. 10105394 - Method of treating graft versus host disease (2018-10-23),

3. 9415072 - Expansion of haemopoietic precursors (2016-08-16),

4. 9301978 - Method of treating graft versus host disease (2016-04-05),

5. 8828375 - Expansion of haemopoietic precursors (2014-09-09),

Title: Michael David Schuster: Innovator in Graft Versus Host Disease Treatment

Introduction

Michael David Schuster is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of medicine, particularly in the treatment of graft versus host disease (GvHD). With a total of five patents to his name, Schuster's work is recognized for its innovative approaches to complex medical challenges.

Latest Patents

Among his latest patents, Schuster has developed a method for treating graft versus host disease. This method involves preventing the development of or treating GvHD complications in a mammalian patient by administering a population of cells enriched for STRO-1 cells and/or progeny thereof and/or soluble factors derived therefrom. This innovative approach aims to improve patient outcomes and enhance the effectiveness of treatments for GvHD.

Career Highlights

Schuster is currently associated with Mesoblast, Inc., a company known for its pioneering work in regenerative medicine. His role at Mesoblast allows him to further his research and development efforts in the field of cell therapy and transplantation.

Collaborations

One of Schuster's notable collaborators is Silviu Itescu, who shares a commitment to advancing medical science and improving patient care through innovative solutions.

Conclusion

Michael David Schuster's contributions to the treatment of graft versus host disease exemplify the impact of innovation in medicine. His work continues to inspire advancements in therapeutic approaches, ultimately benefiting patients in need.

Profile summary based on public USPTO records.